Karyopharm Therapeutics (KPTI) Reports Positive Phase 1/2 Eltanexor Data
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the presentation of Phase 1/2 clinical data for its novel, second-generation oral SINE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)